Peer-Reviewed Journal Details
Mandatory Fields
Doultsinos, D;Carlesso, A;Chintha, C;Paton, JC;Paton, AW;Samali, A;Chevet, E;Eriksson, LA
2020
June
Febs Journal
Peptidomimetic-based identification of FDA-approved compounds inhibiting IRE1 activity
Published
Optional Fields
UNFOLDED PROTEIN RESPONSE SELECTIVE-INHIBITION IRE1-ALPHA CANCER PEPTIDES DOCKING GLIDE
Inositol-requiring enzyme 1 (IRE1) is a bifunctional serine/threonine kinase and endoribonuclease that is a major mediator of the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress. Tumour cells experience ER stress due to adverse environmental cues such as hypoxia or nutrient shortage and high metabolic/protein-folding demand. To cope with those stresses, cancer cells utilise IRE1 signalling as an adaptive mechanism. Here, we report the discovery of the FDA-approved compounds methotrexate, cefoperazone, folinic acid and fludarabine phosphate as IRE1 inhibitors. These were identified through a structural exploration of the IRE1 kinase domain using IRE1 peptide fragment docking and further optimisation and pharmacophore development. The inhibitors were verified to have an impact on IRE1 activityin vitroand were tested for their ability to sensitise human cell models of glioblastoma multiforme (GBM) to chemotherapy. We show that all molecules identified sensitise glioblastoma cells to the standard-of-care chemotherapy temozolomide (TMZ).
1742-464X
10.1111/febs.15372
Grant Details
Publication Themes